Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000345161

Medchemexpress LLC Tolinapant | 1799328-86-1 | 99.81% | 539.68 | 1 ML
SDP

Catalog No. 5000345161
Encompass_Preferred

Tolinapant (ASTX660) is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).

  • Orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP)
  • Being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas
  • Demonstrates antiproliferative activity against human MDA-MB-231 cells with an IC50 of 1.8 nM
  • Shows efficacy in HCC1806 xenografts in mice by causing moderate tumor growth inhibition
  • Available with a purity of 99.81%

Catalog No. 50-003-45161 Supplier Medchemexpress LLC Supplier No. HY10956550MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Tolinapant (ASTX660) is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).

  • Orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP)
  • Being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas
  • Demonstrates antiproliferative activity against human MDA-MB-231 cells with an IC50 of 1.8 nM
  • Shows efficacy in HCC1806 xenografts in mice by causing moderate tumor growth inhibition
  • Available with a purity of 99.81%

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.